SG-LAB-MAY

1234567891011121314151617181920212223242526272829303132333435
Across
  1. 3. Location for testing new therapies
  2. 4. Control used to simulate treatment
  3. 6. Common unit in dose measurement
  4. 9. Type of trial where treatment is concealed
  5. 12. Trial halted before completion: ___ stop
  6. 13. Primary doctor overseeing a trial (abbr.)
  7. 15. IRB stands for Institutional ___ Board
  8. 16. Investigator’s Brochure (abbr.)
  9. 17. Long-term study: follow-___
  10. 18. Subject group not receiving treatment
  11. 20. Acronym for Randomized Controlled Trial (abbr.)
  12. 21. Type of clinical trial that tests a treatment
  13. 23. Phase ___ – first stage of human testing
  14. 25. ___-label – all treatment details visible
  15. 26. ___ review – assessment by peers
  16. 27. Consent must be given ___ (freely)
  17. 29. Participants are often called ___
  18. 30. U.S. database of registered trials
  19. 33. Adverse ___ – undesirable effect
  20. 34. Organization that regulates drugs (abbr.)
  21. 35. Clinical research ___ (supports investigators)
Down
  1. 1. a request for authorization from FDA to administer an investigational drug or biological product to humans
  2. 2. Study conducted without bias (2 words)
  3. 4. Favorable outcome or improvement seen in response to treatment
  4. 5. Predefined outcome used to assess a treatment
  5. 7. Ideal trial design: randomized, double-blind, placebo-controlled (2 words, no space)
  6. 8. Type of assignment that removes bias
  7. 10. ___ – pioneer of clinical trials
  8. 11. Small group selected to represent a larger population
  9. 13. Study of how the body processes drugs
  10. 14. Pre-trial testing phase (animal/in vitro)
  11. 19. A group or treatment pathway in a clinical trial
  12. 22. Essential code for ethical research (1947)
  13. 24. Informed ___ (ethical requirement)
  14. 28. Common reference point in clinical comparisons
  15. 31. Form used for data entry (abbr.)
  16. 32. Documented test procedures (abbr.)